PIK3CA and head and neck squamous cell carcinoma: LOXO-783 is an allosteric inhibitor designed for PIK3CA hotspot mutations and its efficacy in solid tumors, including HNSCC, is currently being evaluated in phase I/II studies (NCT05307705).